Anti-CTLA-4 Antibody Binding Profiles for Lower-Adverse-Effect Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-CTLA-4 antibodies like ipilimumab and tremelimumab have significant adverse effects and are not always effective in reducing immune suppression in the tumor microenvironment, limiting their efficacy in cancer treatment.
Innovation Solution
Development of polypeptides, such as scFvs and antibodies, with high specificity and affinity to CTLA-4, including VH and VL domains, which can be used in diagnostic and therapeutic applications to reduce immune suppression and treat cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-CTLA-4 antibodies (ipilimumab and tremelimumab) are used to block CTLA-4 signaling, then immune suppression is reduced and anti-tumor activity is enhanced, but significant adverse effects occur and efficacy is not always achieved
Solution Approach 1:
The patent applies parameter changes by modifying the binding characteristics of anti-CTLA-4 antibodies. Specifically, the invention develops antibodies with altered affinity parameters (Kd values) and binding kinetics to achieve optimal therapeutic effect while reducing adverse effects. The patent describes antibodies with varying affinities for CTLA-4, demonstrating that adjusting binding parameters can resolve the contradiction between efficacy and safety
Solution Approach 2:
The patent applies local quality by creating antibodies with specific binding properties targeted to particular aspects of CTLA-4 function. The invention develops antibodies that bind to specific epitopes on CTLA-4 with differentiated characteristics, allowing selective modulation of immune suppression without triggering widespread adverse effects. Each antibody variant has tailored binding properties suited for specific therapeutic contexts
2Reliability
If high affinity binding to CTLA-4 is achieved to maximize immune suppression reduction, then therapeutic effect is improved, but adverse effects increase
Solution Approach 1:
The patent applies partial or excessive action by developing a series of antibody variants with progressively different affinity levels. The invention demonstrates that partial binding (moderate affinity) can achieve sufficient therapeutic effect without the excessive action (high affinity) that causes adverse effects. The patent describes multiple antibody variants with graded binding strengths, allowing selection of the optimal partial action level for each therapeutic context
Data Source
AI summary
Compositions and methods are presented in which selected polypeptide compounds bind to CTLA-4. Most typically, binding is mediated by selected VH and/or VL domains, and preferred compounds are prepared as scFv, IgG, or CAR.